avelumab + CMP-001

Avelumab + CMP-001 is an investigational combination therapy studied primarily in advanced solid tumors. **Avelumab** is a fully human IgG1 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with the PD-1 receptor and thereby enhancing T-cell mediated anti-tumor activity. **CMP-001** is a CpG-A oligodeoxynucleotide encapsulated in a virus-like particle, functioning as a Toll-like receptor 9 (TLR9) agonist to stimulate innate and adaptive immune responses by activating plasmacytoid dendritic cells and increasing local interferon production[1][2][4]. The combination is designed to synergize immune checkpoint blockade (by avelumab) with innate immune activation (by CMP-001), potentially increasing anti-tumor efficacy. Notably, CMP-001 has a known risk for cytokine release syndrome when combined with avelumab[4]. Developer-led clinical trials have studied this regimen in various advanced malignancies, typically employing avelumab as an intravenous infusion and CMP-001 as intratumoral or subcutaneous injections[2]. The combination is under evaluation for dosing, safety, pharmacodynamics, and preliminary antitumor activity, including in phase 1b/2 trials in metastatic solid tumors[1][2][4]. Development is led by Pfizer (for avelumab) and Checkmate Pharmaceuticals (for CMP-001).